**Supplementary Table 1. Association of variables and in-hospital mortality in severe COVID-19 patients in univariable Cox regression analysis.**

|  |  |  |
| --- | --- | --- |
| **Variables** | **HR (95% CI)** | ***P* value** |
| Age | 1.06 (1.05, 1.08) | <0.001 |
| Gender (Female vs Male) | 0.54 (0.36, 0.79) | 0.002 |
| Diabetes | 1.51 (0.92, 2.45) | 0.100 |
| Hypertension | 1.38 (0.92, 2.07) | 0.124 |
| COPD | 2.81 (1.30, 6.07) | 0.008 |
| CKD | 3.26 (1.43, 7.44) | 0.005 |
| Smoking | 1.69 (1.04, 2.75) | 0.033 |
| Admission glucose | 1.10 (1.06, 1.13) | <0.001 |
| Admission lymphocyte counts | 0.14 (0.08, 0.25) | <0.001 |
| Admission neutrophil counts | 1.25 (1.21, 1.29) | <0.001 |
| Admission platelet counts | 0.99 (0.99, 1.00) | <0.001 |
| Admission hemoglobin | 1.01 (1.00, 1.02) | 0.227 |
| Admission CRP | 1.01 (1.01, 1.01) | <0.001 |
| Admission SpO2 | 0.92 (0.91, 0.93) | <0.001 |
| Admission LDH | 1.00 (1.00, 1.00) | <0.001 |
| Admission AST | 1.00 (1.00, 1.00) | <0.001 |
| Admission ALT | 1.00 (1.00, 1.01) | <0.001 |
| Admission D-Dimer | 1.09 (1.06, 1.12) | <0.001 |
| Admission Creatinine | 1.00 (1.00, 1.00) | 0.019 |
| Admission BUN | 1.07 (1.05, 1.09) | <0.001 |
| Systemic corticosteroid use | 4.93 (3.17, 7.68) | <0.001 |
| ***Cox regression with time-varying exposure*** |
| Systemic corticosteroid use | 6.41 (4.09, 10.04) | <0.001 |

COVID-19 = coronavirus disease 2019; HR = hazard ratio; CI = confidence interval; COPD = chronic obstructive pulmonary disease; CKD = chronic kidney disease; CRP = C-reactive protein; LDH = lactate dehydrogenase; AST = aspartate aminotransferase; ALT = alanine aminotransferase; BUN = blood urea nitrogen.

**Supplementary Table 2. Baseline comparison between corticosteroid use and no corticosteroid use groups after inverse probability of treatment weighted in severe COVID-19 patients.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables** | **No (n=1645)** | **Yes (n=1511)** | ***P* value** | **SMD** |
| **Age, y** | 63.0 (51.0, 71.0) | 62.0 (50.0, 70.0) | 0.422 | 0.068 |
| **Female, n (%)** | 807 (49.0) | 735 (48.6) | 0.919 | 0.009 |
| **Comorbid conditions, n (%)** |  |  |  |  |
| Diabetes  | 207 (12.6) | 223 (14.8) | 0.497 | 0.064 |
| Hypertension  | 396 (24.1) | 377 (25.0) | 0.824 | 0.021 |
| COPD | 50 (3.1) | 73 (4.8) | 0.401 | 0.089 |
| Cancer | 22 (1.3) | 24 (1.6) | 0.763 | 0.020 |
| CKD | 30 (1.8) | 31 (2.0) | 0.836 | 0.014 |
| Smoking | 249 (15.1) | 182 (12.0) | 0.358 | 0.091 |
| **Admission laboratory values** |  |  |  |  |
| Admission glucose, mmol/L | 6.1 (5.1, 7.8) | 6.4 (5.4, 7.8) | 0.129 | 0.123 |
| Lymphocyte counts, 109/L | 0.9 (0.6, 1.3) | 1.0 (0.7, 1.5) | 0.229 | 0.184 |
| Neutrophil counts, 109/L | 3.9 (2.7, 5.7) | 4.0 (2.7, 5.5) | 0.769 | 0.112 |
| Platelet counts, 109/L | 194.0 (140.0, 245.9) | 198.0 (150.0, 264.0) | 0.298 | 0.110 |
| Hemoglobin, g/L | 126.2 (117.0, 137.0) | 127.0 (114.0, 139.0) | 0.769 | 0.008 |
| CRP, mg/L | 26.9 (4.3, 59.9) | 31.4 (10.7, 44.6) | 0.150 | 0.007 |
| SpO2, % | 98.0 (95.0, 99.0) | 96.9 (95.0, 99.0) | 0.050 | 0.109 |
| LDH, U/L | 235.3 (179.8, 341.4) | 231.0 (188.8, 315.0) | 0.961 | 0.143 |
| AST, U/L | 27.0 (18.0, 40.4) | 27.9 (21.0, 40.0) | 0.111 | 0.004 |
| ALT, U/L | 25.8 (16.0, 38.0) | 24.2 (17.0, 36.8) | 0.926 | 0.010 |
| D-Dimer, mg/L | 0.5 (0.3, 1.0) | 0.4 (0.2, 0.8) | 0.067 | 0.151 |
| Creatinine, μmol/L | 70.0 (58.1, 85.4) | 71.0 (60.0, 90.0) | 0.448 | 0.127 |
| BUN, mmol/L | 4.6 (3.6, 6.2) | 4.6 (3.6, 5.8) | 0.540 | 0.173 |

COVID-19 = coronavirus disease 2019; SMD = standardized mean difference; COPD = chronic obstructive pulmonary disease; CKD = chronic kidney disease; CRP = C-reactive protein; LDH = lactate dehydrogenase; AST = aspartate aminotransferase; ALT = alanine aminotransferase; BUN = blood urea nitrogen.

**Supplementary Table 3. Baseline comparison between corticosteroid use and no corticosteroid use groups after propensity score matching in severe COVID-19 patients.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variables** | **No (n=360)** | **Yes (n=360)** | ***P* value** |
| **Age, y** | 62.0 (52.0, 70.0) | 62.0 (50.0, 70.0) | 0.502 |
| **Female, n (%)** | 173 (48.1) | 178 (49.4) | 0.766 |
| **Comorbid conditions, n (%)** |  |  |  |
| Diabetes  | 47 (13.1) | 46 (12.8) | 1.000 |
| Hypertension  | 84 (23.3) | 79 (21.9) | 0.722 |
| COPD | 12 (3.3) | 11 (3.1) | 1.000 |
| Cancer | 4 (1.1) | 5 (1.4) | 1.000 |
| CKD | 8 (2.2) | 6 (1.7) | 0.788 |
| Smoking | 44 (12.2) | 44 (12.2) | 1.000 |
| **Admission laboratory values** |  |  |  |
| Admission glucose, mmol/L | 6.2 (5.3, 8.1) | 6.5 (5.4, 7.7) | 0.257 |
| Lymphocyte counts, 109/L | 0.8 (0.6, 1.1) | 0.8 (0.6, 1.1) | 0.824 |
| Neutrophil counts, 109/L | 3.9 (2.6, 5.3) | 3.9 (2.7, 5.5) | 0.887 |
| Platelet counts, 109/L | 190.5 (144.5, 239.0) | 185.5 (144.0, 241.0) | 0.674 |
| Hemoglobin, g/L | 128.0 (115.0, 138.0) | 127.0 (116.0, 138.0) | 0.926 |
| CRP, mg/L | 33.5 (7.7, 66.9) | 34.2 (15.6, 51.6) | 0.547 |
| SpO2, % | 97.0 (95.0, 99.0) | 96.0 (94.0, 98.0) | 0.002 |
| LDH, U/L | 253.7 (201.0, 339.4) | 257.6 (197.5, 327.0) | 0.736 |
| AST, U/L | 27.2 (18.7, 41.0) | 28.8 (22.0, 42.5) | 0.035 |
| ALT, U/L | 25.8 (16.1, 38.8) | 24.3 (16.0, 39.0) | 0.875 |
| D-Dimer, mg/L | 0.4 (0.3, 0.8) | 0.4 (0.2, 0.9) | 0.032 |
| Creatinine, μmol/L | 70.1 (59.7, 85.7) | 70.4 (60.0, 87.0) | 0.723 |
| BUN, mmol/L | 4.5 (3.6, 6.0) | 4.5 (3.5, 5.7) | 0.373 |

COVID-19 = coronavirus disease 2019; COPD = chronic obstructive pulmonary disease; CKD = chronic kidney disease; CRP = C-reactive protein; LDH = lactate dehydrogenase; AST = aspartate aminotransferase; ALT = alanine aminotransferase; BUN = blood urea nitrogen.

**Supplementary Table 4.** **Association of variables and in-hospital mortality in critical COVID-19 patients in univariable Cox regression analysis.**

|  |  |  |
| --- | --- | --- |
| **Variables** | **HR (95% CI)** | ***P* value** |
| Age | 1.02 (1.00, 1.03) | 0.020 |
| Gender (Female vs Male) | 0.70 (0.44, 1.10) | 0.123 |
| Diabetes | 1.15 (0.70, 1.87) | 0.588 |
| Hypertension | 1.06 (0.69, 1.63) | 0.792 |
| COPD | 0.64 (0.29, 1.41) | 0.270 |
| Cancer | 0.83 (0.20, 3.39) | 0.797 |
| CKD | 1.36 (0.59, 3.12) | 0.468 |
| Smoking | 1.64 (1.04, 2.59) | 0.035 |
| Admission glucose | 1.07 (1.03, 1.11) | 0.001 |
| Admission lymphocyte counts | 0.53 (0.31, 0.88) | 0.015 |
| Admission neutrophil counts | 1.09 (1.06, 1.13) | <0.001 |
| Admission platelet counts | 1.00 (0.99, 1.00) | 0.075 |
| Admission hemoglobin | 1.00 (0.99, 1.02) | 0.570 |
| Admission CRP | 1.01 (1.00, 1.01) | <0.001 |
| Admission SpO2 | 0.94 (0.93, 0.95) | <0.001 |
| Admission LDH | 1.00 (1.00, 1.00) | <0.001 |
| Admission AST | 1.00 (1.00, 1.00) | 0.803 |
| Admission ALT | 1.00 (1.00, 1.00) | 0.869 |
| Admission D-Dimer | 1.07 (1.05, 1.10) | <0.001 |
| Admission Creatinine | 1.00 (1.00, 1.00) | <0.001 |
| Admission BUN | 1.05 (1.03, 1.07) | <0.001 |
| Systemic corticosteroid use | 3.13 (1.76, 5.57) | <0.001 |
| ***Cox regression with time-varying exposure*** |
| Systemic corticosteroid use | 4.10 (2.34, 7.18) | <0.001 |

COVID-19 = coronavirus disease 2019; HR = hazard ratio; CI = confidence interval; COPD = chronic obstructive pulmonary disease; CKD = chronic kidney disease; CRP = C-reactive protein; LDH = lactate dehydrogenase; AST = aspartate aminotransferase; ALT = alanine aminotransferase; BUN = blood urea nitrogen.

**Supplementary Table 5.** **Baseline comparison between corticosteroid use and no corticosteroid use groups after inverse probability of treatment weighted in critical COVID-19 patients.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables** | **No (n=240)** | **Yes (n=253)** | ***P* value** | **SMD** |
| **Age, y** | 67.0 (57.0, 75.1) | 67.0 (58.0, 74.6) | 0.893 | 0.046 |
| **Female, n (%)** | 84.1 (35.1) | 100.1 (39.6) | 0.578 | 0.094 |
| **Comorbid conditions, n (%)** |  |  |  |  |
| Diabetes  | 66 (27.4) | 57 (22.6) | 0.553 | 0.112 |
| Hypertension  | 90 (37.7) | 111 (43.7) | 0.484 | 0.122 |
| COPD | 21 (8.8) | 23 (9.2) | 0.934 | 0.011 |
| Cancer | 3 (1.2) | 6 (2.3) | 0.569 | 0.080 |
| CKD | 15 (6.2) | 19 (7.5) | 0.760 | 0.055 |
| Smoking | 78 (32.6) | 55 (21.6) | 0.238 | 0.250 |
| **Admission laboratory values** |  |  |  |  |
| Admission glucose, mmol/L | 6.5 (5.6, 7.9) | 7.1 (5.8, 8.4) | 0.264 | 0.023 |
| Lymphocyte counts, 109/L | 0.7 (0.4, 1.0) | 0.7 (0.4, 1.1) | 0.558 | 0.021 |
| Neutrophil counts, 109/L | 4.7 (3.3, 8.3) | 4.8 (3.4, 7.6) | 0.974 | 0.070 |
| Platelet counts, 109/L | 186.0 (146.5, 261.7) | 186.5 (136.0, 241.2) | 0.506 | 0.198 |
| Hemoglobin, g/L | 123.5 (102.1, 135.0) | 124.3 (114.0, 136.0) | 0.345 | 0115 |
| CRP, mg/L | 51.1 (18.6, 132.5) | 68.2 (20.7, 133.6) | 0.746 | 0.059 |
| SpO2, % | 96.1 (89.0, 98.5) | 94.5 (90.0, 98.0) | 0.434 | 0.205 |
| LDH, U/L | 306.4 (188.5, 572.9) | 307.4 (205.0, 524.2) | 0.937 | 0.029 |
| AST, U/L | 30.9 (22.6, 57.2) | 32.5 (20.0, 47.7) | 0.448 | 0.141 |
| ALT, U/L | 22.5 (16.8, 41.8) | 24.8 (15.7, 41.0) | 0.669 | 0.111 |
| D-Dimer, mg/L | 0.9 (0.5, 2.0) | 0.6 (0.4, 1.6) | 0.173 | 0.085 |
| Creatinine, μmol/L | 81.6 (64.5, 115.0) | 75.5 (60.8, 104.4) | 0.425 | 0.118 |
| BUN, mmol/L | 6.0 (4.4, 8.3) | 5.5 (4.3, 8.9) | 0.558 | 0.150 |

COVID-19 = coronavirus disease 2019; SMD = standardized mean difference; COPD = chronic obstructive pulmonary disease; CKD = chronic kidney disease; CRP = C-reactive protein; LDH = lactate dehydrogenase; AST = aspartate aminotransferase; ALT = alanine aminotransferase; BUN = blood urea nitrogen.

**Supplementary Table 6.** **Baseline comparison between corticosteroid use and no corticosteroid use groups after propensity score matching in critical COVID-19 patients.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variables** | **No (n=60)** | **Yes (n=60)** | ***P* value** |
| **Age, y** | 70.0 (53.0, 86.5) | 67.5 (58.5, 77.0) | 0.727 |
| **Female, n (%)** | 25 (41.7) | 27 (45.0) | 0.854 |
| **Comorbid conditions, n (%)** |  |  |  |
| Diabetes  | 14 (23.3) | 14 (23.3) | 1.000 |
| Hypertension  | 22 (36.7) | 22 (36.7) | 1.000 |
| COPD | 8 (13.3) | 7 (11.7) | 1.000 |
| Cancer | 1 (1.7) | 1 (1.7) | 1.000 |
| CKD | 4 (6.7) | 3 (5.0) | 1.000 |
| Smoking | 12 (20.0) | 13 (21.7) | 1.000 |
| **Admission laboratory values** |  |  |  |
| Admission glucose, mmol/L | 6.7 (5.6, 7.8) | 6.8 (5.7, 7.9) | 0.637 |
| Lymphocyte counts, 109/L | 0.8 (0.6, 1.1) | 0.8 (0.5, 1.2) | 0.927 |
| Neutrophil counts, 109/L | 4.2 (3.3, 6.9) | 3.9 (3.0, 5.7) | 0.228 |
| Platelet counts, 109/L | 187.0 (149.0, 246.5) | 184.5 (135.5, 237.0) | 0.234 |
| Hemoglobin, g/L | 122.2 (108.5, 135.5) | 119.5 (112.5, 134.5) | 0.950 |
| CRP, mg/L | 50.1 (22.6, 125.9) | 61.7 (20.8, 128.7) | 0.854 |
| SpO2, % | 97.2 (95.0, 99.0) | 97.0 (93.7, 99.0) | 0.472 |
| LDH, U/L | 251.2 (166.6, 408.2) | 266.3 (194.6, 359.9) | 0.954 |
| AST, U/L | 26.8 (19.4, 50.8) | 30.9 (20.1, 44.0) | 0.929 |
| ALT, U/L | 21.1 (15.1, 38.0) | 22.4 (16.2, 34.1) | 0.719 |
| D-Dimer, mg/L | 0.7 (0.4, 1.7) | 0.5 (0.3, 0.8) | 0.061 |
| Creatinine, μmol/L | 80.0 (57.0, 100.8) | 73.5 (57.3, 105.6) | 0.781 |
| BUN, mmol/L | 5.7 (4.1, 7.9) | 5.5 (4.2, 7.0) | 0.644 |

COVID-19 = coronavirus disease 2019; COPD = chronic obstructive pulmonary disease; CKD = chronic kidney disease; CRP = C-reactive protein; LDH = lactate dehydrogenase; AST = aspartate aminotransferase; ALT = alanine aminotransferase; BUN = blood urea nitrogen.

**Supplementary Table 7.** **Blood glucose level and lymphocyte counts in severe and critical COVID-19 patients with or without corticosteroid use.**

|  |  |  |
| --- | --- | --- |
| **Variables** | **Median (IQR)** | ***P* value\*** |
| ***Severe cases*** |
| **Blood glucose level, mmol/L** |  |  |
|  No corticosteroid use | 5.6 (4.9, 6.7) | <0.001 |
|  Before corticosteroid use | 6.2 (5.3, 7.7) | <0.001 |
|  During corticosteroid use | 7.2 (5.9, 9.0) | - |
|  After corticosteroid use | 5.5 (4.8, 7.0) | <0.001 |
| **Lymphocyte counts, 109/L** |  |  |
|  No corticosteroid use | 1.3 (1.0, 1.6) | <0.001 |
|  Before corticosteroid use | 0.8 (0.6, 1.0) | 0.782 |
|  During corticosteroid use | 0.8 (0.5, 1.0) | - |
| After corticosteroid use | 1.2 (0.9, 1.5) | <0.001 |
| ***Critical cases*** |
| **Blood glucose level, mmol/L** |  |  |
| No corticosteroid use | 6.4 (5.2, 7.7) | <0.001 |
| Before corticosteroid use | 7.1 (5.9, 8.8) | <0.001 |
| During corticosteroid use | 7.5 (6.3, 9.6) | - |
| After corticosteroid use | 7.0 (6.0, 10.4) | <0.001 |
| **Lymphocyte counts, 109/L** |  |  |
| No corticosteroid use | 1.1 (0.8, 1.5) | <0.001 |
| Before corticosteroid use | 0.6 (0.5, 1.0) | 0.214 |
| During corticosteroid use | 0.7 (0.4, 1.0) | - |
| After corticosteroid use | 0.9 (0.6, 1.3) | <0.001 |

COVID-19 = coronavirus disease 2019; IQR = interquartile range.

\* P value is compared with the blood glucose level or lymphocyte counts during corticosteroid use.